Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A dec exp |
Therapy | Buthionine sulfoximine |
Indication/Tumor Type | ovarian cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A dec exp | ovarian cancer | predicted - sensitive | Buthionine sulfoximine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770). | 30686770 |
PubMed Id | Reference Title | Details |
---|---|---|
(30686770) | Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. | Full reference... |